Samantha Prout - Dec 31, 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Chief Accounting Officer
Signature
/s/ Christian Formica, Attorney-in-Fact
Stock symbol
FOLD
Transactions as of
Dec 31, 2023
Transactions value $
-$350,119
Form type
4
Date filed
1/3/2024, 06:30 PM
Previous filing
Dec 28, 2023
Next filing
Jan 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Tax liability -$331K -23.4K -19.16% $14.19 98.6K Dec 31, 2023 Direct
transaction FOLD Common Stock Award $0 +25.3K +25.62% $0.00 124K Jan 2, 2024 Direct F1
transaction FOLD Common Stock Tax liability -$18.7K -1.31K -1.06% $14.24 122K Jan 2, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Award $0 +43.6K $0.00 43.6K Jan 2, 2024 Common Stock 43.6K $14.24 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 2, 2025 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
F2 These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.